Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding.
- Mechanism
- Curator reviewed · 1 reference
Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage.
- Primary indication
- Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis.Curator reviewed · 4 structured indications
- Formula / weight
- C8H15NO2 · 157.2102 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1986
- Also known as
- Tranexmic acid · Tranhexamic acid · Trans AMCHA · trans-Amcha · trans-Tranexamic acid
- Code names
- CL-65336 · LB1148 · RP-18429
- Brand names
Resolves to
GYDJEQRTZSCIOI-LJGSYFOKSA-NSMILESNC[C@H]1CC[C@@H](CC1)C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Tranexamic acid, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account